INDEGENE
Back to Balance Sheet
|
INDEGENE Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹56 Cr | ₹435 Cr | ₹584 Cr | ₹80 Cr | ₹27 Cr |
What is the latest Total Non-Current Liabilities ratio of INDEGENE ?
Year | Total Non-Current Liabilities |
---|---|
Mar2025 | ₹56 Cr |
Mar2024 | ₹435 Cr |
Mar2023 | ₹584 Cr |
Mar2022 | ₹80 Cr |
Mar2021 | ₹27 Cr |
How is Total Non-Current Liabilities of INDEGENE Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2025 | ₹56 Cr | -87.12 | |
Mar2024 | ₹435 Cr | -25.54 | |
Mar2023 | ₹584 Cr | 630.10 | |
Mar2022 | ₹80 Cr | 198.58 | |
Mar2021 | ₹27 Cr | - |
Compare Total Non-Current Liabilities of peers of INDEGENE
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
INDEGENE | ₹13,122.7 Cr | -1.7% | -4.9% | -13.5% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹416,273.0 Cr | 2.5% | 4.1% | -0.8% | Stock Analytics | |
DIVIS LABORATORIES | ₹176,604.0 Cr | 0.5% | -2.9% | 35.7% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹126,316.0 Cr | 6.2% | 9.3% | 17.9% | Stock Analytics | |
CIPLA | ₹125,993.0 Cr | 4.9% | 2.9% | 1.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹107,795.0 Cr | 2.1% | 1.2% | -5% | Stock Analytics |
INDEGENE Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
INDEGENE | -1.7% |
-4.9% |
-13.5% |
SENSEX | -1.5% |
-2.5% |
0.2% |
You may also like the below Video Courses